Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics study of three QRL-101 formulations in healthy participants
NL-OMON59813Phase 1Completed
- Sponsor
- QurAlis
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of QRL-101 in amyotrophic lateral sclerosis (ALS), sponsored by QurAlis. Started Jan 2025; status: completed.
02
Drugs
QRL-101
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON59813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59813.